Figure 2.

BMSCs from risk-stratified AML patients do not impair in vivo multilineage repopulating function of CB-CD34⁺ HSPCs. (A) Representative FACS analysis of the graft. The human graft is identified as the CD45⁺HLA-ABC⁺ fraction. The CD45⁺ human graft comprises B-lymphoid cells (CD19⁺), myeloid cells (CD33⁺) as well as immature CD34⁺ and CD34⁺CD38⁻ cells. (B) Long-term multilineage hematopoietic reconstitution in the IT, CL, PB and spleen of NSG mice sacrificed 6-7 weeks after intra BM injection of CB-CD34⁺ HSPCs alone (n=5) or co-cultured for 4 days in BMSCs from HD (n=5) or AML patients (n=15; LR, n=5; IR, n=5; HR, n=5). n=90 mice, 4 per donor/patient. (C) Multilineage and multiorgan human chimerism demonstrating that AML-BMSCs do not negatively impact migration of HSPCs from the IT. No differences in the graft composition were found between CD34⁺ HSPCs co-cultured with BMSCs from HD or risk-stratified AML patients. (D) Long-term BM hematopoietic reconstitution assessed upon serial transplantation of primografted cells. IT: injected tibia; CL: contralateral tibia and femur; PB: peripheral blood.